NeurAxon appoints Dr Thomas Lategan VP of regulatory affairs
This article was originally published in Scrip
Executive Summary
NeurAxon, a US developer of next-generation pain therapeutics, has named Dr Thomas Lategan vice-president of regulatory affairs. He has more than 20 years' experience in pharmaceutical regulatory affairs and project management, having most recently served as vice-president of regulatory affairs at Panacos Pharmaceuticals.